The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Artificial Intelligence Against Covid-19: An Early Review
Open accessAbstract
Artificial Intelligence (AI) is a potentially powerful tool in the fight against the COVID- 19 pandemic. Since the outbreak of the pandemic, there has been a scramble to use AI. This article provides an early, and necessarily selective review, discussing the contribution of AI to the fight against COVID-19, as well as the current constraints on these contributions. Six areas where AI can contribute to the fight against COVID-19 are discussed, namely i) early warnings and alerts, ii) tracking and prediction, iii) data dashboards, iv) diagnosis and prognosis, v) treatments and cures, and vi) social control. It is concluded that AI has not yet been impactful against COVID-19. Its use is hampered by a lack of data, and by too much data. Overcoming these constraints will require a careful balance between data privacy and public health, and rigorous human-AI interaction. It is unlikely that these will be addressed in time to be of much help during the present pandemic. In the meantime, extensive gathering of diagnostic data on who is infectious will be essential to save lives, train AI, and limit economic damages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
A general reinforcement learning algorithm that masters chess, shogi, and Go through self-play
Silver, D., Hubert, T., Schrittwieser, J., Antonoglou, I., Lai, M., Guez, A., Lanctot, M., Sifre, L., Kumaran, D., Graepel, T., et al. (2018) · Science · doi:10.1126/science.aar6404 · Cited by 3,562
Deep Convolutional Neural Networks for Image Classification: A Comprehensive Review
Rawat, W., & Wang, Z. (2017) · Neural Computation · doi:10.1162/neco_a_00990 · Cited by 3,503
COVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117
Cited by
Chamola, V., Hassija, V., Gupta, V., & Guizani, M. (2020) · IEEE Access · doi:10.1109/access.2020.2992341 · Cited by 1,099
“• Gero, AI-powered drug discovery and drug repurposing platform developed by a group of scientists in Singapore, has assisted in the identification of several existing drugs, including a drug named Afatinib (used to treat non-small cell lung cancer), that could potentially be used to treat the COVID-19 [185].”
BackgroundInfluentialArtificial Intelligence and COVID-19: Deep Learning Approaches for Diagnosis and Treatment
Jamshidi, M., Lalbakhsh, A., Talla, J., Peroutka, Z., Hadjilooei, F., Lalbakhsh, P., Jamshidi, M., Spada, L. L., Mirmozafari, M., Dehghani, M., et al. (2020) · IEEE Access · doi:10.1109/access.2020.3001973 · Cited by 551
Digital technology use during COVID ‐19 pandemic: A rapid review
Vargo, D., Zhu, L., Benwell, B., & Yan, Z. (2021) · Human Behavior and Emerging Technologies · doi:10.1002/hbe2.242 · Cited by 459
Artificial intelligence vs COVID-19: limitations, constraints and pitfalls
Naudé, W. (2020) · AI & SOCIETY · doi:10.1007/s00146-020-00978-0 · Cited by 368
Self-citationA review of modern technologies for tackling COVID-19 pandemic
Kumar, A., Gupta, P. K., & Srivastava, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.05.008 · Cited by 347
Metadata
- Authors
- Naudé, W.
- Venue
- SSRN Electronic Journal
- Publisher
- Elsevier BV
- Published
- 2020
- ISSN
- 1556-5068 (ISSN-L)
- OpenAlex
- W3015634610
- Cited by
- 170
- References
- 4
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Artificial Intelligence Against Covid-19: An Early Review. https://app.cochat.ai/papers/10.2139/ssrn.3568314
- The paper
- Naudé, W. (2020). Artificial Intelligence Against Covid-19: An Early Review. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3568314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.